Evidence map›Paper›PMID 39389668›Full record

ArticleMethods in enzymology2024

RADD: A real-time FRET-based biochemical assay for DNA deaminase studies.

Christopher A Belica, Patricia C Hernandez, Michael A Carpenter, Yanjun Chen, William L Brown, Reuben S Harris, Hideki Aihara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in enzymology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher A BelicaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, United States; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States. Electronic address: belic028@umn.edu.
Patricia C HernandezDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, United States; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Michael A CarpenterDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, United States; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, United States.
Yanjun ChenDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, United States.
William L BrownDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, United States; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, United States; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, United States.
Hideki AiharaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, United States; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States. Electronic address: aihar001@umn.edu.

Funding

PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Michael Allen Carpenter · 2019 to 2026
$14.5M
Structural studies of viral replication and invasionR35GM118047 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hideki Aihara · 2016 to 2026
$6.3M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
NCI NIH HHS P01 CA234228NIAID NIH HHS T32 AI083196NIGMS NIH HHS R35 GM118047
6 · The paper itself

Abstract

In recent years, the connection between APOBEC3 cytosine deaminases and cancer mutagenesis has become ever more apparent. This growing awareness and lack of inhibitory drugs has created a distinct need for biochemical tools that can be used to identify and characterize potential inhibitors of this family of enzymes. In response to this challenge, we have developed a Real-time APOBEC3-mediated DNA Deamination (RADD) assay. The RADD assay provides a rapid, real-time fluorescence readout of APOBEC3 DNA deamination and serves as a crucial addition to the existing APOBEC3 biochemical and cellular toolkit. This method improves upon contemporary DNA deamination assays by offering a more rapid and quantifiable readout as well as providing a platform that is readily adaptable to a high-throughput format for inhibitor discovery. In this chapter we provide a detailed guide for the usage of the RADD assay for the characterization of APOBEC3 enzymes and potential inhibitors.

Indexed as

DNAFluorescence Resonance Energy TransferAPOBEC DeaminasesCytidine DeaminaseDeaminationEnzyme AssaysEnzyme InhibitorsHumansAPOBEC DeaminasesCytidine DeaminaseDNAEnzyme InhibitorsAPOBEC3CancerCytidine deaminaseFluorescence resonance energy transfer (FRET)High‐throughput screening (HTS)Real-time assay

Identifiers

PMID39389668
PMCPMC11483159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.